OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Mikhael on Unmet Needs to Be Addressed in Multiple Myeloma

March 27th 2024

Joseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.

Dr Richardson on Escalating Rates of Uterine Cancer Among Asian Americans

March 27th 2024

Michael Richardson, MD, discusses escalating uterine cancer rates among Asian Americans.

Dr Mehta on the Advantages of MRI-Guided Adaptive Radiotherapy in Cancer Care

March 26th 2024

Minesh Mehta, MD, discusses how MRI-guided adaptive radiation therapy systems may improve disease outcomes in cancer care.

Dr Olivares on the Use of Focal Therapy in Localized Prostate Cancer

March 26th 2024

Ruben Olivares, MD, discusses the evolving role for focal radiation therapy in the management of prostate cancer.

Dr Koo on PSMA PET Imaging in Prostate Cancer

March 26th 2024

Phillip J. Koo, MD, discusses the use of PSMA PET imaging in prostate cancer.

Dr Dizon on the Prevalence of Sexual Challenges in Patients With Breast Cancer

March 26th 2024

Don S. Dizon, MD, on the prevalence of sexual complications in patients with breast cancer.

Dr Konecny on the MIRASOL trial and Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

March 26th 2024

Gottfried Konecny, MD, discusses the MIRASOL trial that evaluated mirvetuximab soravtansine in FRα-positive platinum-resistant recurrent ovarian cancer.

Dr Finkelstein on the Significance of the 2024 ACRO Summit

March 26th 2024

Steven E. Finkelstein, MD, DABR, FACRO, on advancing radiation oncology and updates from the 2024 ACRO Summit.

Dr Xu on Changes in Systemic Therapy in RCC

March 26th 2024

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Dr Spratt on Metastasis-Directed Therapy and Hypofractionation in Prostate Cancer

March 26th 2024

Daniel Spratt, MD, discusses the integration of metastasis-directed therapy and hypofractionation in prostate cancer.

Dr Brown on the Implications of Genomic Data for Pirtobrutinib Use in CLL

March 25th 2024

Jennifer R. Brown, MD, PhD, discusses results from a genomic analysis of responses with pirtobrutinib in patients with chronic lymphocytic leukemia.

Dr Grajales-Cruz on Future Research Directions With Teclistamab in R/R Multiple Myeloma

March 25th 2024

Ariel Grajales-Cruz, MD, discusses research elucidating the role of teclistamab monotherapy for patients with relapsed/refractory multiple myeloma.

Dr Spratt on the Use of Radiation in Low– and High-Risk Prostate Cancer

March 22nd 2024

Daniel Spratt, MD, discusses the use of radiation therapy in low- and high-risk prostate cancer.

Dr Amini on High-Risk Factors Associated With Cardiac Toxicities in Lung Cancer

March 22nd 2024

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

Dr Xu on Treatment Decision-Making in RCC

March 22nd 2024

Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.

Dr Koo on Treating Various Stages of Prostate Cancer

March 22nd 2024

Philip J. Koo, MD, discusses the treatment of patients with prostate cancer throughout the different stages of their disease.

Dr Mahtani on the Expansion of Targeted Therapies in HER2+ Breast Cancer

March 22nd 2024

Reshma L. Mahtani, DO, discusses how the expansion of HER2-targeted agents has impacted the management of HER2-positive breast cancer.

Dr Borgen on the Debate Over Routine MRI Testing in Early-Stage Breast Cancer

March 22nd 2024

Patrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.

Dr Konecny on the FDA Approval of Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

March 22nd 2024

Gottfried E. Konecny, MD, discusses the FDA approval of mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant ovarian cancer.

Dr D’Amico on Advancements in High-Risk Prostate Cancer Diagnosis and Management

March 22nd 2024

Anthony V. D'Amico, MD, PhD, on the advancements in high-risk prostate cancer diagnosis and management